Research Article
Abnormal Movements of Japanese Infants following Treatment with Midazolam in a Neonatal Intensive Care Unit: Incidence and Risk Factors
Table 1
Characteristics of the infants.
| | Abnormal movement (+) | Abnormal movement (−) | -value |
| | Case (male/female) | 9 (4/5) | 110 (67/43) | 0.34 | | Gestational age (weeks)a | 30.1 (5.8) | 34.3 (5.8) | 0.04 | | Apgar score 1b | 3.5 (1–8) | 7 (0–10) | 0.07 | | Apgar score 5b | 7 (5–9) | 8 (1–10) | 0.68 | | Birth weight (g)a | 1492 (1045) | 2109 (1074) | 0.10 | | Postnatal age when midazolam administration was started (days)a |
17.2 (26.8) | 41.9 (59.3) | 0.25 | | Postconceptional age when midazolam administration was started (weeks)a |
32.5 (5.0) | 40.1 (9.1) | 0.01 | | Body weight when midazolam administration was started (g)a | 1531 (961) | 2592 (1331) | 0.02 | | Dose of midazolam (mg·kg−1·h−1)a |
0.14 (0.06) | 0.21 (0.10) | 0.05 | | Duration of midazolam administration (h)a |
7.2 (13.3) | 162.3 (234.2) | <0.0001 |
|
|
aData are expressed as mean (standard deviation).
bData are expressed as median (range).
|
